Skip to content

Study · Randomized controlled trial · 2025

8 results

Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.

Zhou J, Husain M, Li Y, Liu W, Shen Z, Vilsbøll T, Ge J

Diabetes, obesity & metabolism24 Jul 2025Cited by 7 (Europe PMC)

PMID40704485 (opens in a new tab)PMCIDPMC12409197 (opens in a new tab)DOI10.1111/dom.16621 (opens in a new tab)PepBankPUB-40704485
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk, semaglutide significantly reduced the risk of primary MACE versus placebo in pooled SUSTAIN 6 and PIONEER 6 data.

    In plain wordsIn people with type 2 diabetes at high heart risk, semaglutide lowered major heart events more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePrimary MACE
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide significantly reduced the risk of primary and expanded MACE
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk, semaglutide significantly reduced the risk of expanded MACE versus placebo in pooled SUSTAIN 6 and PIONEER 6 data.

    In plain wordsIn people with type 2 diabetes at high heart risk, semaglutide lowered a wider set of heart events more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseExpanded MACE
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide significantly reduced the risk of primary and expanded MACE
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk, the reduction in cardiovascular death with semaglutide versus placebo was not significant.

    In plain wordsIn people with type 2 diabetes at high heart risk, semaglutide did not significantly change deaths from heart causes versus placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeCardiovascular death
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with a nonsignificant risk reduction of CV and all-cause death versus placebo in the overall population
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk, the reduction in all-cause death with semaglutide versus placebo was not significant.

    In plain wordsIn people with type 2 diabetes at high heart risk, semaglutide did not significantly change deaths from any cause versus placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAll-cause death
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with a nonsignificant risk reduction of CV and all-cause death versus placebo in the overall population
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk, the semaglutide effect on MACE was consistent across subgroups of prior cardiovascular disease and baseline BMI.

    In plain wordsIn people with type 2 diabetes at high heart risk, semaglutide effects on heart events were similar across prior heart disease and BMI groups.

    Peptide
    Semaglutide
    Outcome
    No significant changeConsistency of MACE effect across subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the effect was consistent across all subgroups (pINT >0.05 for all comparisons).
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In the SUSTAIN 6 population, semaglutide reduced the risk of new or worsening nephropathy versus placebo (HR 0.64).

    In plain wordsIn people with type 2 diabetes at high heart risk, semaglutide lowered new or worsening kidney disease more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseNew or worsening nephropathy in SUSTAIN 6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    hazard ratio
    0.64 HR
    SUSTAIN 6

    Source sentences

    Summary
    Semaglutide consistently reduced nephropathy risk versus placebo in the SUSTAIN 6 population (HR [95% CI]: 0.64 [0.46; 0.88], p = 0.0054)
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk, the semaglutide effect on nephropathy was consistent across all subgroups.

    In plain wordsIn people with type 2 diabetes at high heart risk, semaglutide effects on kidney disease were similar across subgroups.

    Peptide
    Semaglutide
    Outcome
    No significant changeConsistency of nephropathy effect across subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and across all subgroups (pINT >0.05 for all comparisons).
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high cardiovascular risk, accounting for body weight change left the semaglutide effect on primary MACE similar to the main analysis.

    In plain wordsIn people with type 2 diabetes at high heart risk, adjusting for weight change left semaglutide effects on heart events similar.

    Peptide
    Semaglutide
    Outcome
    No significant changePrimary MACE after adjustment for body weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When accounting for BW changes, treatment effects on primary MACE risk in the overall population and by BMI subgroups remained similar compared with the results of the main analysis.
    2 context sentences
    Summary · context
    Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non-fatal myocardial infarction, or non-fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all-cau…
    Summary · context
    Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.